Loading…
Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination
n-Butyric acid has previously been shown in vitro to suppress T cell alloresponses and beyond that to induce a state of alloantigen-specific hyporesponsiveness suggesting a potential relevance for suppressing alloresponses also in vivo. The clinical use of butyrate salt derivatives, however, is limi...
Saved in:
Published in: | Transplant immunology 1999-12, Vol.7 (4), p.221-227 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | n-Butyric acid has previously been shown
in vitro to suppress T cell alloresponses and beyond that to induce a state of alloantigen-specific hyporesponsiveness suggesting a potential relevance for suppressing alloresponses also
in vivo. The clinical use of butyrate salt derivatives, however, is limited by an extremely short half-life due to rapid metabolism. This prompted us to investigate the effect of butyric acid derivatives with prolonged residence time
in vivo on T cell alloresponses
in vitro and further to explore the immuno-suppressive capacity of esterified
n-butyric acid
in vivo. First, the effect of three butyric acid esters, i.e. glucose pentabutyrate, diacetone glucose butyrate and tributyrin on T cell proliferation in a human mixed lymphocyte culture (MLC) was evaluated. All three derivatives were found to inhibit T cell alloresponses in a concentration-dependent manner. Based on the ED50 values, glucose pentabutyrate was found to be most effective in inhibiting T cell alloreactivity
in vitro (11 μM), followed by diacetone glucose butyrate (122 μM), tributyrin (146 μM) and sodium butyrate (539 μM). Because of its favourable
in vitro properties, glucose pentabutyrate was chosen for
in vivo experiments. To test the effect of this compound on allograft survival
in vivo, in the second part of this study, heterotopic heart transplants were performed in a high responder fully allogeneic rat strain combination (Brown Norway to Lewis strain rats). We found that intraperitoneal (i.p.) injection of glucose pentabutyrate at 500 mg/kg/day (day 0 and daily up to 12 days post-transplant) induced a significant prolongation of allograft survival as compared to animals treated with vehicle (glycerol formal, i.p.) alone (14.1 ± 6.3 versus 9.6 ± 3.2 days,
p = 0.036), whereby at lower dosage (100 mg/kg/day) no such effect was observed (10.2 ± 2.1 days,
p = 0.21). Our findings suggest that stable prodrugs of
n-butyric acid might have potential clinical relevance for inhibiting alloresponses
in vivo. |
---|---|
ISSN: | 0966-3274 1878-5492 |
DOI: | 10.1016/S0966-3274(99)80006-9 |